Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SECUKINUMAB Cause Intentional product use issue? 1,881 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 1,881 reports of Intentional product use issue have been filed in association with SECUKINUMAB (COSENTYX). This represents 1.2% of all adverse event reports for SECUKINUMAB.

1,881
Reports of Intentional product use issue with SECUKINUMAB
1.2%
of all SECUKINUMAB reports
1,290
Deaths
1,350
Hospitalizations

How Dangerous Is Intentional product use issue From SECUKINUMAB?

Of the 1,881 reports, 1,290 (68.6%) resulted in death, 1,350 (71.8%) required hospitalization, and 1,412 (75.1%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 1,881 reports have been filed with the FAERS database.

What Other Side Effects Does SECUKINUMAB Cause?

Drug ineffective (27,434) Psoriasis (21,976) Pain (15,244) Arthralgia (13,769) Fatigue (9,406) Psoriatic arthropathy (8,900) Pruritus (8,755) Malaise (8,570) Rash (8,023) Condition aggravated (7,536)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which SECUKINUMAB Alternatives Have Lower Intentional product use issue Risk?

SECUKINUMAB vs SELADELPAR LYSINE SECUKINUMAB vs SELEGILINE SECUKINUMAB vs SELENIUM SECUKINUMAB vs SELENIUM SULFIDE SECUKINUMAB vs SELEXIPAG

Related Pages

SECUKINUMAB Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue SECUKINUMAB Demographics